Here are the latest G-BA decisions from the G-BA meeting held on 1 Aug 2024 on the early benefit assessments of Rezzayo, Briumvi, Veoza, Veltassa, and Vanflyta.
A complete database of all previous G-BA resolutions is available upon request.
- Rezzayo (rezafungin) invasive Candida infections – Orphan drug, Hint of not-quantifiable additional benefit
- Briumvi (ublituximab); relapsing-remitting multiple sclerosis – Indication of minor additional benefit in one of two subgroups
- Veoza (fezolinetant); vasomotor symptoms (VMS) associated with menopause – Hint of minor additional benefit in one of two subgroups
- Veltassa (patiromer); new indication: hyperkalaemia, ≥ 12 to ≤ 17 years – Additional benefit not proven
- Vanflyta (quizartinib) acute myeloid leukaemia, FLT3-ITD-positive – Additional benefit not proven
- Fabhalta (iptacopan); paroxysmal nocturnal hemoglobinuria – Request for RWE collection
Follow me on Instagram to never miss the latest G-BA decisions: